Depression

 
Three-Quarters of US Adults Want to Be Asked About Mental Health in Primary Care Visits: New Survey
November 22, 2024

Approximately 70% of US adults surveyed hope their primary care clinician will ask about their mental health during an appointment, regardless of the presenting issue.

Depression, Anxiety in Youth with Chronic Pain: Daily Dose
October 15, 2024

Your daily dose of the clinical news you may have missed.

Effectiveness of Suicide Care Implementation in Primary Care: Daily Dose
October 14, 2024

Your daily dose of the clinical news you may have missed.

FDA Black-Box Warnings on Antidepressants Linked to Reduced Treatment, Increased Risk of Suicide Among Youth
October 08, 2024

The FDA warnings were intended to increase physician monitoring for suicidal thoughts and behaviors but have had dramatic unintended consequences.

Youth with Chronic Pain Face Greater Symptoms of Depression, Anxiety than Pain-Free Peers
October 02, 2024

Findings from a systematic review and meta-analysis showed 1 in 3 youth with chronic pain were diagnosed with anxiety and 1 in 8 were diagnosed with depression.

Mental Health Conditions Common in Primary Care Settings: Daily Dose
October 02, 2024

Your daily dose of the clinical news you may have missed.

Suicide Attempts Reduced by 25% with Integrated Primary Care Intervention
October 01, 2024

A 14% increase in the rates of primary care safety planning within 2 weeks of a negative screening was associated 25% drop in the rate of attempted suicides.

High Percentage of Patients Seek Mental Health Care from PCPs, According to New Large Analysis
September 23, 2024

One in 9 primary care encounters involved a mental health condition, according to an analysis of over 350 million primary care visits.

Mental Health Among Adolescents With Obesity: Daily Dose
September 16, 2024

Your daily dose of the clinical news you may have missed.

Lebrikizumab Therapy Improved QoL, Mental Health Outcomes in Patients with Atopic Dermatitis
September 10, 2024

In a study of persons with moderate-to-severe atopic dermatitis, lebrikizumab monotherapy for 16 weeks resulted in improved quality of life and mental health.